This deck reviews modern longevity science across three frames: the biological hallmarks of aging (López-Otín et al., 2013; updated 2023), the geographic patterns known as Blue Zones (Buettner, 2005), and the interventions with current human or animal evidence. We separate established findings from speculation, and frame the field's central distinction: lifespan (years lived) versus healthspan (years lived in good function). For most readers, the second matters more than the first.
Aging is the progressive loss of physiological integrity. It is the largest single risk factor for cancer, cardiovascular disease, neurodegeneration, type 2 diabetes, and sarcopenia.
The classical Gompertz law (1825) observed that mortality risk doubles roughly every eight years after age thirty. Modern biology asks whether that exponential is malleable. Two endpoints distinguish the field:
The 2013 paper "The Hallmarks of Aging" (Cell) identified nine cellular and molecular processes whose dysregulation drives aging. The 2023 update expanded the list to twelve.
| Hallmark | |
|---|---|
| 1. | Genomic instability |
| 2. | Telomere attrition |
| 3. | Epigenetic alterations |
| 4. | Loss of proteostasis |
| 5. | Disabled macroautophagy |
| 6. | Deregulated nutrient sensing (mTOR, IGF-1) |
| 7. | Mitochondrial dysfunction |
| 8. | Cellular senescence |
| 9. | Stem-cell exhaustion |
| 10. | Altered intercellular communication |
| 11. | Chronic inflammation ("inflammaging") |
| 12. | Dysbiosis (microbiome aging) |
When cells suffer DNA damage or telomere erosion they may permanently exit the cycle while remaining metabolically active — the senescent phenotype. Senescent cells secrete a soup of inflammatory factors (the SASP — senescence-associated secretory phenotype) that damages neighboring tissue.
Animal models show that selective elimination of senescent cells (with "senolytics" like dasatinib + quercetin) extends healthspan. Human trials are early but ongoing in idiopathic pulmonary fibrosis and frailty.
Caloric restriction — eating ~20–40% below ad libitum — extends lifespan in yeast, worms, flies, mice, and (variably) rhesus monkeys. The NIH-funded CALERIE-2 trial (2007–2012) showed that 12% restriction in healthy humans for two years lowered cardiometabolic risk markers and slowed biological-age clocks.
Mechanistically, CR engages nutrient-sensing pathways: lower mTOR, lower IGF-1, higher AMPK, increased autophagy. Many of these effects are mimicked by intermittent fasting and time-restricted eating, though long-term human evidence is thinner.
"The most reliable lever in longevity biology is to eat less. The most difficult lever to pull is to eat less."
Journalist Dan Buettner, working with demographer Gianni Pes and Michel Poulain, identified five regions with unusual concentrations of healthy centenarians: Okinawa (Japan), Sardinia (Italy), Nicoya (Costa Rica), Ikaria (Greece), and Loma Linda (Seventh-Day Adventist enclave, California).
The shared "Power 9" pattern: natural movement throughout the day; sense of purpose; downshifting (stress reduction); the 80% rule (stop eating before full); plant-led diet; moderate wine; community belonging; faith-based participation; family priority.
Skeptics (notably Saul Justin Newman, 2024) argue that some Blue Zone signals reflect record-keeping errors and pension fraud rather than biology. Even so, the lifestyle pattern aligns broadly with the best-supported epidemiologic findings.
A coastal Mediterranean village — geography aligned with several Blue Zone hypotheses. Photo: Unsplash.
| Compound | Mechanism | Status |
|---|---|---|
| Metformin | AMPK activator, ↓ mTOR | TAME trial pending |
| Rapamycin | mTOR inhibitor | Strong rodent data; small human trials |
| Senolytics (D+Q) | Clear senescent cells | Early human trials |
| NAD+ precursors (NMN, NR) | Restore NAD+ | Mixed human evidence |
| GLP-1 agonists | ↓ inflammation, ↓ weight | Cardiovascular benefit established |
| Spermidine | Autophagy | Observational + small RCTs |
VO₂ max is one of the strongest predictors of all-cause mortality identified in any cohort study (Mandsager et al., JAMA Network Open, 2018). Comparing the lowest fitness quintile to the highest, mortality risk roughly halves. The relationship is dose-dependent and continuous — there is no upper threshold of benefit.
Strength matters too. Grip strength, leg power, and lean mass independently predict mortality and disability. Resistance training preserves all three. The American practice of treating exercise as optional adjunct rather than first-line therapy is medically anomalous.
Physician Peter Attia frames healthspan around the four chronic diseases that account for ~80% of deaths in the developed world: atherosclerotic cardiovascular disease, cancer, neurodegenerative disease (Alzheimer's, Parkinson's), and type 2 diabetes / metabolic dysfunction.
The proposal: shift medicine from "Medicine 2.0" (treat-when-symptomatic) to "Medicine 3.0" — early, individualized risk-factor management decades before clinical onset. Lipidology, advanced cardiac imaging, continuous glucose monitoring, and detailed cognitive testing are tools in this kit.
Steve Horvath's epigenetic clock (2013) demonstrated that DNA methylation patterns at ~350 CpG sites predict chronological age within ~3 years. Newer "second-generation" clocks (PhenoAge, GrimAge, DunedinPACE) predict mortality and morbidity better than chronological age alone, and respond to interventions in months.
Clocks are useful research tools and unsettled clinical tools. Their interventional validation — does slowing the clock translate to fewer events? — is an active question.
Sleep duration shows a U-shaped mortality curve, with optimum near 7 hours. Sleep apnea, insomnia, and shift-work all increase cardiometabolic risk. Glymphatic clearance during deep sleep removes amyloid-β and tau — proteins that accumulate in Alzheimer's disease. Treating sleep is currently one of the highest-leverage and least-prescribed interventions for healthspan.
Holt-Lunstad's meta-analyses (2010, 2015) found that strong social relationships are associated with ~50% lower mortality risk — comparable in magnitude to quitting smoking. Loneliness elevates cortisol, inflammation, and cardiovascular risk. The 2023 US Surgeon General advisory called loneliness a public-health epidemic. Whatever else longevity science discovers, the social variable will likely remain in the top tier.
Long-form conversations with researchers (David Sinclair, Matt Kaeberlein, Tom Dayspring, Anna Lembke) on longevity science. Many full episodes are free on YouTube.
Books: Peter Attia, Outlive (2023); David Sinclair, Lifespan (2019); Dan Buettner, The Blue Zones (2008); Steven Austad, Methuselah's Zoo (2022).
Strong evidence for healthspan benefit: regular exercise, not smoking, sleep adequacy, social connection, weight management, blood pressure control, vaccination. Moderate evidence: caloric restriction, time-restricted eating, omega-3, statins for primary prevention in elevated-risk adults. Weak/early: most named "anti-aging" supplements, biological-age-clock guided treatment, senolytics in healthy humans.
The longevity industry runs ahead of its evidence. The conservative reading: do the things with strong evidence, do them consistently for decades, and watch the field for what becomes proven next.
Educational content. Pharmacologic interventions discussed are research-stage in the longevity context. Consult a clinician before initiating any.